NCT03172325 - Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA | Biotech Hunter

Enrollment

136

Participants

Timeline

Start Date

November 18, 2015

Primary Completion Date

August 17, 2016

Study Completion Date

January 4, 2017

Conditions

Active Rheumatoid Arthritis

Interventions

DRUG

Adalimumab

40 mg Adalimumab every other week is administered subcutaneously to all the patients.

DRUG

Methotrexate

15 mg Methotrexate is weekly administered to all the patients.

DRUG

Folic Acid

At least 1 mg Folic acid is daily administered to all the patients.

DRUG

Prednisolone

7.5 mg Prednisolone is daily administered to all the patients.

Trial Locations (10)

Alzahra Hospital, Isfahan

Besat 4 Clinic, Kerman

Ghaem Hospital, Mashhad

Razi Hospital, Rasht

Imam Ali Clinic, Shahr-e Kord

Hafez Hospital, Shiraz

Noor Medical Complex, Tabriz

Imam Reza Hospital (501 Artesh), Tehran

Iran Rheumatism Center, Tehran

Loghman Hakim Hospital, Tehran